A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether adding tirzepatide to ixekizumab helps people with active psoriatic arthritis and overweight or obesity achieve better physical function after 12 months of treatment.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 200 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-03 · est. completion 2027-11

Where 55 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06864026 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC

Main thing measured	Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy
Sponsor	Eli Lilly and Company
Conditions studied	Psoriatic Arthritis, Overweight or Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06864026 ↗